Sort   by:  
 Page size 
MetabolomicsAberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma (Xenograft assays)

Glioblastoma (GBM) is a common and deadly form of brain tumor in adults. Dysregulated metabolism in GBM offers an opportunity to deploy metabolic interventions as precise therapeutic strategies. To identify the molecular drivers and the modalities by which different molecular subgroups of GBM exp...

2022-11-08 | MTBLS730 | MetaboLights
MetabolomicsAberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma (Stem cell and cell line assays)

Glioblastoma (GBM) is a common and deadly form of brain tumor in adults. Dysregulated metabolism in GBM offers an opportunity to deploy metabolic interventions as precise therapeutic strategies. To identify the molecular drivers and the modalities by which different molecular subgroups of GBM exp...

2022-11-08 | MTBLS4708 | MetaboLights
TranscriptomicsCopy number analysis of human glioblastoma multiforme
Copy number analysis of human GBM samples were performed, and a high frequency of deletions of the PTPRD gene on chromosome 9p23-24.1 were identified. Keywords: SNP microarray, glioblastoma multiforme, copy number, amplification, deletion Genomic DNA from 58 GBM tumor samples were hybridized to Aff...
ORGANISM(S): Homo sapiens 
2009-01-04 | E-GEOD-13021 | biostudies-arrayexpress
MetabolomicsCell-intrinsic metabolic phenotypes identified in glioblastoma patients using mass spectrometry imaging of 13C-labeled glucose metabolism

Transcriptomic studies attempted to classify glioblastoma (GB) into subtypes that predict survival and that have different therapeutic vulnerabilities1-3. Here we identified three metabolic subtypes: glycolytic, oxidative and a mixed glycolytic/oxidative by mass spectrometry imaging of rapidly ex...

2025-05-08 | MTBLS12176 | MetaboLights
GenomicsBase resolution maps of mutations, 5-methylcytosine and 5-hydroxymethylcytosine, and transcriptome of blood, tumour and margin samples from a glioblastoma multiforme patient
Glioblastoma multiforme is the most common and aggressive type of brain cancer. Little is known about the complex relationship between genomic and epigenomic as tumour progresses. We present the following base resolution whole genome maps of matched tumour/margin and blood samples from a glioblastom...
ORGANISM(S): Homo sapiens 
2017-02-24 | E-MTAB-5171 | biostudies-arrayexpress
TranscriptomicsGlioblastoma microvesicles transport RNA and proteins
Glioblastoma tumour cells release microvesicles (exosomes) containing mRNA, miRNA and angiogenic proteins. These microvesicles are taken up by normal host cells, such as brain microvascular endothelial cells. By incorporating an mRNA for a reporter protein into these microvesicles, we demonstrate th...
ORGANISM(S): Homo sapiens 
2008-11-15 | E-GEOD-13470 | biostudies-arrayexpress
TranscriptomicsProfiling by array of human Glioblastoma multiforme (GBM) tumor samples to asses the intra-tumoral heterogeneity in genomic copy number aberrations
Glioblastoma multiforme (GBM) is a highly heterogeneous disease that shows an wide range of genetic abnormalities in comparison to other astrocytic tumors. We have extracted between 4 and 8 tumor subsamples from different areas of the malignant tissue that were at least 1cm apart. Our aim to asses t...
ORGANISM(S): Homo sapiens 
2013-02-15 | E-MTAB-1215 | biostudies-arrayexpress
MetabolomicsHypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239
Background: Elevated choline kinase alpha (ChoK) levels are observed in most solid tumors, including glioblastomas (GBM), and ChoK inhibitors have demonstrated limited efficacy in GBM models. Given that hypoxia is associated with resistance to GBM therapy, we hypothesized that tumor hypoxia c...
2024-06-18 | MTBLS6212 | MetaboLights
ProteomicsHigh-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity
Glioblastoma, the most aggressive primary brain cancer, has dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we here syste...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000090357 | MassIVE
ProteomicsIdentification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. F...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000084343 | MassIVE
Sort   by:  
 Page size